A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)

Ak-Kaif, Mohammed Ahmed Imran (2023) A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI). PhD thesis, Universiti Sains Malaysia.

[img]
Preview
 PDF
Download (1MB) | Preview

Abstract

The P2Y12 receptor inhibitors, especially clopidogrel, are common antiplatelet drugs used for the prevention of recurrent adverse cardiovascular events among patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Several factors may affect the effectiveness of antiplatelet therapy, including genetic variations in CYP450 enzymes. Loss of function (LOF) carriers of the CYP2C19 gene are associated with the decreased metabolism of clopidogrel into active metabolites via CYP2C19 enzyme, leading to decreased platelet inhibition. This causes an increased risk of recurrent cardiovascular events. Drug regulatory authorities suggested using alternative P2Y12 inhibitor, which is ticagrelor. Therefore, this study aims to investigate the adverse effects, and CYP2C19 genetic variations of clopidogrel and ticagrelor treatment among CAD patients undergoing PCI.

Item Type: Thesis (PhD)
Subjects: R Medicine > RS Pharmacy and materia medica > RS1-441 Pharmacy and materia medica
Divisions: Pusat Pengajian Sains Farmasi (School of Pharmacy) > Thesis
Depositing User: Mr Aizat Asmawi Abdul Rahim
Date Deposited: 03 May 2024 00:33
Last Modified: 03 May 2024 00:33
URI: http://eprints.usm.my/id/eprint/60515

Actions (login required)

View Item View Item
USM Repository is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.
Share